Both treated and non-treated patients had higher CLU+/αSMA+ CAF ratios in BRCA-mut patients compared to WT, supporting the notion that CAF distribution is driven by the tumor genotype and is not altered by neoadjuvant treatment regimens (See Supplementary Data 1 for clinical information). Here, ACTA1 is linked to neoplasm.